Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer.
Sung C, An J, Lee S, Park J, Lee KS, Kim IH, Han JY, Park YH, Kim JH, Kang EJ, Hong MH, Kim TY, Lee JC, Lee JL, Yoon S, Choi CM, Lee DH, Yoo C, Kim SW, Jeong JH, Seo S, Kim SY, Kong SY, Choi JK, Park SR. Sung C, et al. Among authors: hong mh. Nat Cancer. 2023 Jun;4(6):844-859. doi: 10.1038/s43018-023-00572-5. Epub 2023 Jun 12. Nat Cancer. 2023. PMID: 37308678
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC. Ahn MJ, et al. Among authors: hong mh. Lancet Oncol. 2019 Dec;20(12):1681-1690. doi: 10.1016/S1470-2045(19)30504-2. Epub 2019 Oct 3. Lancet Oncol. 2019. PMID: 31587882 Clinical Trial.
Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response.
Kim MH, Kim JH, Lee JM, Choi JW, Jung D, Cho H, Kang H, Hong MH, Heo SJ, Kim SH, Choi EC, Kim DH, Park YM, Kim S, Yoon SO, Koh YW, Cho BC, Kim HR. Kim MH, et al. Among authors: hong mh. Br J Cancer. 2020 May;122(11):1649-1660. doi: 10.1038/s41416-020-0796-8. Epub 2020 Apr 1. Br J Cancer. 2020. PMID: 32235905 Free PMC article.
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH, You GL, Ahn MJ, Kim SW, Hong MH, Han JY, Ock CY, Lee JS, Oh IJ, Lee SY, Kim CH, Min YJ, Choi YH, Ryu JS, Park SH, Ahn HK, Shim BY, Lee KH, Lee SY, Kim JS, Yi J, Choi SK, An H, Kang JH. Park JH, et al. Among authors: hong mh. J Cancer Res Clin Oncol. 2021 Aug;147(8):2459-2469. doi: 10.1007/s00432-021-03527-4. Epub 2021 Feb 1. J Cancer Res Clin Oncol. 2021. PMID: 33523301
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
Cho BC, Han JY, Kim SW, Lee KH, Cho EK, Lee YG, Kim DW, Kim JH, Lee GW, Lee JS, Shim BY, Kim JS, Chun SH, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Lee Y, Lee DH, Kang JA, Lee N, Kwon MJ, Espenschied C, Yablonovitch A, Ahn MJ. Cho BC, et al. Among authors: hong mh. J Thorac Oncol. 2022 Apr;17(4):558-567. doi: 10.1016/j.jtho.2021.11.025. Epub 2021 Dec 24. J Thorac Oncol. 2022. PMID: 34958928 Free article. Clinical Trial.
446 results